Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.

Autor: Lin CY; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Chang WT; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan., Su PL; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Biomedical Engineering, College of Engineering, National Cheng Kung University, Tainan, Taiwan., Kuo CW; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Yang J; Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Lin CC; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan., Lin SH; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Publikováno v: JAMA network open [JAMA Netw Open] 2024 Dec 02; Vol. 7 (12), pp. e2448364. Date of Electronic Publication: 2024 Dec 02.

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.

Autor: Lu S; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shun_lu@hotmail.com., Ahn MJ; Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Reungwetwattana T; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Özgüroğlu M; Department of Internal Medicine, Division of Medical Oncology, Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Türkiye., Kato T; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan., Yang JC; Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan., Huang M; Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China., Fujiki F; ICESP-Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Inoue T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Quang LV; Department of Oncology, Hanoi Medical University, Hanoi, Vietnam., Sriuranpong V; Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Vicente D; Medical Oncology Department, Hospital Universitario Virgen de Macarena, Sevilla, Spain., Fuentes C; Department of Oncology, Centro Médico Dra. De Salvo, Buenos Aires, Argentina., Chaudhry AA; Late-stage Development, Oncology R&D, AstraZeneca, Gaithersburg, USA., Poole L; Biometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Armenteros Monterroso E; Late-stage Development, Oncology R&D, AstraZeneca, Barcelona, Spain., Rukazenkov Y; Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., van der Gronde T; Late-stage Development, Oncology R&D, AstraZeneca, New York., Ramalingam SS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Dec; Vol. 35 (12), pp. 1116-1125. Date of Electronic Publication: 2024 Sep 16.

Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation.

Autor: Hu S; State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China., Tong L; Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Qin Q; State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China., Wen J; Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.; University of Chinese Academy of Sciences, Beijing 100049, China., Li Y; Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Feng F; Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Wu K; School of Basic Medical Sciences, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou 511436, China., Zhou Y; State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China., Shang J; School of Basic Medical Sciences, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou 511436, China., Wang J; Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China., Liu J; State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China., Xie H; Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.; University of Chinese Academy of Sciences, Beijing 100049, China., Lu X; State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China.; Department of Hematology, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou 510632, China.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Nov 28; Vol. 67 (22), pp. 20531-20558. Date of Electronic Publication: 2024 Nov 13.

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients.

Autor: Wang X; Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, Chongqing, 400016, China., Zhu J; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China., Li L; Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, Chongqing, 400016, China., Zhao Q; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China., Huang Y; Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, Chongqing, 400016, China., Wen C; Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, Chongqing, 400016, China., Chen D; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. danchen@cqmu.edu.cn., Wu L; Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, Chongqing, 400016, China. lxwu@cqmu.edu.cn.

Publikováno v: Molecular medicine (Cambridge, Mass.) [Mol Med] 2024 Nov 11; Vol. 30 (1), pp. 209. Date of Electronic Publication: 2024 Nov 11.

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.

Autor: Hibino M; Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, 1-5-1 Tsujido Kandai, Fujisawa, Kanagawa, 251-0041, Japan. m-hibino@ctmc.jp., Imamura Y; Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki, Chuo, Kobe, Hyogo, 650-0017, Japan., Shimoyama R; Department of General Surgery, Shonankamakura General Hospital, 1370-1, Okamoto, Kamakura, Kanagawa, 247-8533, Japan., Fukui T; Department of Respiratory Medicine, Shonan Kamakura General Hospital, 1370-1, Okamoto, Kamakura, Kanagawa, 247-8533, Japan., Fukai R; Department of General Thoracic Surgery, Shonan Kamakura General Hospital, 1370-1, Okamoto, Kamakura, Kanagawa, 247-8533, Japan., Iwase A; Department of Respiratory Medicine, Chibanishi General Hospital, 107-1, Kanegasaku, Matsudo, Chiba, 270-2251, Japan., Tamura Y; Department of General Internal Medicine, Oosumi Kanoya Hospital Kanoya, 6081-1, Shinkawa, Kanoya, Kagoshima, 893-0015, Japan., Chihara Y; Department of Respiratory Medicine, Uji Tokushukai Medical Center, 145, Ishibashi, Makishima, Uji, Kyoto, 611-0041, Japan., Okabe T; Department of Medical Oncology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan., Uryu K; Department of Medical Oncology, Yao Tokushukai General Hospital, 1-17, Wakakusa-cho, Yao, Osaka, 581-0011, Japan., Okuda T; Department of Health Data Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.; Human Health Sciences, Kyoto University Graduate School of Medicine, 53, Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan., Taguri M; Department of Health Data Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan., Minami H; Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki, Chuo, Kobe, Hyogo, 650-0017, Japan.; Cancer Center, Kobe University Hospital, Kusunoki, Chuo, Kobe, Hyogo, 650-0017, Japan.

Publikováno v: Targeted oncology [Target Oncol] 2024 Nov; Vol. 19 (6), pp. 925-939. Date of Electronic Publication: 2024 Sep 20.